<DOC>
	<DOC>NCT01306591</DOC>
	<brief_summary>Age-related macular degeneration (AMD) is one of primary blinding eye disease among people over 65 years in China. The anti-VEGF antibody treatment is proved useful for Neovascular Age-related Macular Degeneration (nAMD) by many studies. Bevacizumab is the only available low-cost type of anti-VEGF drug currently in China. This study is a multi-center, randomized trial of Bevacizumab effective dose and safety for nAMD. This study is to explore the effective therapeutic approach that the majority of patients in China can bear establishing a suitable treatment for China.</brief_summary>
	<brief_title>Bevacizumab for Neovascular Age-related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Clinical diagnosis of neovascular Agerelated macular degeneration Signed informed consent No other ocular fundus diseases</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>neovascular age-related macular degeneration</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Multicenter Randomized Study</keyword>
</DOC>